-
EP3532501
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3532501
| EP3532501 - ANTI-RANKL ANTIBODIES AND USES THEREOF [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 11.02.2021 Database last updated on 02.11.2024 | |
| Former | Request for examination was made Status updated on 02.08.2019 | ||
| Former | The international publication has been made Status updated on 05.05.2018 | ||
| Former | unknown Status updated on 10.11.2017 | Most recent event Tooltip | 01.10.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 / US | [2019/36] | Inventor(s) | 01 /
KORYTKO, Andrew Ihor c/o Eli Lilly and Company P.O. Box 6288 Indianapolis Indiana 46206-6288 / US | 02 /
OBUNGU, Victor H. c/o Eli Lilly and Company P.O. Box 6288 Indianapolis Indiana 46206-6288 / US | [2019/36] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2019/36] | Kent, Lindsey Ruth Eli Lilly and Company Limited Lilly Research Center Erl Wood Manor Sunninghill Road, Windlesham Surrey GU20 6PH / GB | Application number, filing date | 17791908.1 | 20.10.2017 | [2019/36] | WO2017US57543 | Priority number, date | US201662414217P | 28.10.2016 Original published format: US 201662414217 P | [2019/36] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2018080914 | Date: | 03.05.2018 | Language: | EN | [2018/18] | Type: | A1 Application with search report | No.: | EP3532501 | Date: | 04.09.2019 | Language: | EN | The application published by WIPO in one of the EPO official languages on 03.05.2018 takes the place of the publication of the European patent application. | [2019/36] | Search report(s) | International search report - published on: | EP | 03.05.2018 | Classification | IPC: | C07K16/28 | [2019/36] | CPC: |
C07K16/2875 (EP,KR,US);
A61P19/10 (EP,KR,US);
A61K2039/505 (EP,KR,US);
C07K2317/34 (EP,KR,US);
C07K2317/76 (EP,KR,US);
C07K2317/92 (EP,KR,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/36] | Title | German: | ANTI-RANKL-ANTIKÖRPER UND VERWENDUNGEN DAVON | [2019/36] | English: | ANTI-RANKL ANTIBODIES AND USES THEREOF | [2019/36] | French: | ANTICORPS ANTI-RANKL ET LEURS UTILISATIONS | [2019/36] | Entry into regional phase | 28.05.2019 | National basic fee paid | 28.05.2019 | Designation fee(s) paid | 28.05.2019 | Examination fee paid | Examination procedure | 25.04.2019 | Amendment by applicant (claims and/or description) | 28.05.2019 | Examination requested [2019/36] | 28.05.2019 | Date on which the examining division has become responsible | 10.02.2021 | Despatch of a communication from the examining division (Time limit: M04) | 03.06.2021 | Reply to a communication from the examining division | 15.12.2022 | Despatch of a communication from the examining division (Time limit: M04) | 21.04.2023 | Reply to a communication from the examining division | 23.07.2024 | Despatch of a communication from the examining division (Time limit: M04) | Fees paid | Renewal fee | 31.10.2019 | Renewal fee patent year 03 | 02.11.2020 | Renewal fee patent year 04 | 01.10.2021 | Renewal fee patent year 05 | 03.10.2022 | Renewal fee patent year 06 | 01.10.2023 | Renewal fee patent year 07 | 01.10.2024 | Renewal fee patent year 08 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [I]WO2014159430 (APEXIGEN INC [US]); | [I]WO2015030701 (PHARM OVERSEAS INC R [US]); | [I]EP3085709 (GENOR BIOPHARMA CO LTD [CN]); | [XPI]WO2016186957 (LILLY CO ELI [US]) | Examination | WO2008088594 | WO2017136195 | by applicant | US6740522 |